Application of a Reliable LC-MS/MS Method for Determination of Rizatriptan in Healthy Subject Samples: Demonstration of Assay Reproducibility by Incurred Sample Reanalysis

Table 2

Absolute matrix effect, relative recovery, and process efficiency for rizatriptan.

A (% CV)	B (% CV)	C (% CV)	Absolute matrix effect; (B/A × 100)	Relative recovery; (C/B × 100)	Process efficiency; (C/A × 100)
LQC
33412 (2.35)	32376 (3.44)	25856 (7.82)	96.9 (95.8)*	79.9 (80.6)*	77.4 (77.2)*
MQC-2
270010 (6.14)	260020 (4.01)	205127 (7.20)	96.3 (96.2)*	78.9 (79.1)*	76.0 (76.1)*
MQC-1
1250559 (6.89)	1198036 (4.58)	1026817 (8.50)	95.8 (98.0)*	85.7 (79.2)*	82.1 (77.6)*
HQC
2485238 (5.21)	2368432 (1.93)	1978173 (7.36)	95.3 (97.3)*	83.5 (80.9)*	79.6 (78.7)*

A: mean area response of six replicate samples prepared in mobile phase (neat samples).
B: mean area response of six replicate samples prepared by spiking in extracted blank plasma.
C: mean area response of six replicate samples prepared by spiking before extraction.
CV: coefficient of variation.
*Values for internal standard, sumatriptan.